HC Wainwright issued their Q2 2025 earnings estimates for Capricor Therapeutics in a report issued on Thursday, March 20th.

Full Year 2024 Results Key Financial Results Revenue: US$22.3m (down 12% from ...

Shares of Capricor Therapeutics (CAPR) are trading up by about 13% on Thursday noon after the company announced ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Capricor Therapeutics (CAPR) released expectation-beating results for the fourth quarter, sending the shares up over 5% in aftermarket trading.

Capricor Therapeutics, Inc.’s CAPR share price has dipped by 10.45%, which has investors questioning if this is right time to ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Capricor Therapeutics ...

Capricor Therapeutics, Inc.’s CAPR share price has surged by 17.51%, which has investors questioning if this is right time to ...

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report), with ...

To get a sense of who is truly in control of Capricor Therapeutics, Inc. (NASDAQ:CAPR), it is important to understand the ownership structure of the business. And the group that holds the biggest ...

Farallon Capital Management LLC bought a new position in Capricor Therapeutics during the 4th quarter worth about $31,056,000. Vanguard Group Inc. grew its holdings in shares of Capricor ...

Capricor Therapeutics announced that the U.S. FDA has accepted its Biologics License Application (BLA) for deramiocel, aimed at treating cardiomyopathy in patients with Duchenne muscular dystrophy ...